IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Orthocell Limited
Orthocell is a Public Company that generates the majority of its income from the Medical and Surgical Equipment Manufacturing industry. In 2025 the company generated total revenue of $6,923,000 including sales and other revenue. The exact number of employees for this organisation is not available. The Chief Executive of Orthocell is Mr Paul Anderson whose official title is Chief Executive Officer & Managing Director. The Chairman of Orthocell is Mr John Van Der Wielen whose official title is Independent Non-Executive Chairman. Orthocell Limited is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Development to date has focused on two main products: CelGro - is a naturally derived collagen medical device designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage. The application of CelGro platform is used in Strite+(dental bone and soft tissue repair procedure) and Remplir (used in peripheral nerve repair). Ortho-ATI - is a first-in-class cell therapy for the treatment of chronic tendon injuries. The unique treatment uses each patient’s tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound-guided injection.
Access this data your way
The Orthocell Limited Industry analysis is available in multiple formats to fit seamlessly into your workflow.
API Data Delivery
Feed trusted, human-driven industry intelligence straight into your platform.
Integrations
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
What's included in this industry analysis
IBISWorld's research coverage on the Orthocell Limited includes market sizing, forecasting, data and analysis. The most recent publication will be as current as of March 2026.
Company Details
What’s this enterprise profile about?
Orthocell Limited, trading as Orthocell, operates under the ABN 57 118 897 135 and was incorporated on 21 March 2006. Orthocell Limited trades on the Australian Securities Exchange under the ticker code ASX:OCC. Orthocell Limited primarily operates in the Medical and Surgical Equipment Manufacturing industry in Australia.
Key Personnel
What’s included in the Key Personnel chapter?
The Key Personnel chapter outlines the principal leadership positions within Orthocell Limited, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
Financials
What’s included in the Financials chapter?
The Financials chapter presents Orthocell Limited’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
Growth & Ratios
What’s included in the Growth & Rations chapter?
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
Operating Segments
What’s included in the Operating Segments chapter?
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which Orthocell Limited operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
Competitor Benchmarking
What’s included in the Competitor Benchmarking chapter?
The Competitor Benchmarking chapter includes a comparative assessment of Orthocell Limited’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
Shareholders
What’s included in the Shareholders chapter?
The Shareholders chapter provides a breakdown of the ownership structure of Orthocell Limited, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
Subsidiaries
What’s included in the Subsidiaries chapter?
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by Orthocell Limited. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
History
What’s included in the History chapter?
The History chapter presents a overview of Orthocell Limited’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
Trusted by industry professionals
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Frequently Asked Questions
What is Orthocell Limited?
Orthocell Limited is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Development to date has focused on two main products: CelGro - is a naturally derived collagen medical device designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage. The application of CelGro platform is used in Strite+(dental bone and soft tissue repair procedure) and Remplir (used in peripheral nerve repair). Ortho-ATI - is a first-in-class cell therapy for the treatment of chronic tendon injuries. The unique treatment uses each patient’s tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound-guided injection.
What industry does Orthocell Limited operate in?
Orthocell Limited, trading as Orthocell, is a Public Company that generates the majority of its income from the Medical and Surgical Equipment Manufacturing industry in Australia.
Where is Orthocell Limited located?
Murray Cod Australia Limited company is based at South Street, Murdoch, Western Australia, Australia.
Who is the CEO of Orthocell Limited?
The Chief Executive Officer & Managing Director of Orthocell Limited is John Van Der Wielen and the Chief Executive Officer & Managing Director is Paul Anderson.
What was Orthocell Limited’s revenue in 2025?
In 2025, Orthocell Limited generated total revenue of approximately $6.9 million.
Cut through the noise with intelligence you can trust
